Ventyx Biosciences

Yahoo Finance • 2 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflamma... Full story

Yahoo Finance • 4 months ago

Ventyx reports positive Phase 2a results for Parkinson's drug

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biotech company with a market capitalization of $181 million, announced Tuesday that its Phase 2a study of VTX3232, an oral NLRP3 inhibitor for early-stage Parkinson’s di... Full story

Yahoo Finance • 4 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative d... Full story

Yahoo Finance • 8 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform developme... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases wit... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases wit... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of VTX9... Full story

Yahoo Finance • 2 years ago

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerability profile Ventyx to host conference c... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases wit... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory dise... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases w... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory dis... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerat... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, w... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day

Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory dise... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences to Host R&D Event on January 26, 2023

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory dise... Full story

Yahoo Finance • 3 years ago

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage Phase 2 trials of VTX958 for psoriatic arthritis and Crohn’s disease are on track to init... Full story